Squamous Cell Skin Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

A deadly form of skin cancer is squamous cell carcinoma. Small, flat cells called squamous cells are present in the skin's epidermis. Round, flat or raised skin tumors frequently form when these cells progress to cancer. On occasion, the skin around the tumor will turn red and swell. The incidence of cSCC is rising globally despite growing public understanding of the risks associated with prolonged sun exposure and the causes of skin cancer. Electrical curettage is a treatment option for cutaneous squamous cell carcinoma (cSCC) of low risk that affects the trunk and extremities. The main options for treating aggressive cSCC are surgical resection and Moss microsurgery; these procedures have comparable cure rates when using the right patients. Radiation therapy is frequently used in conjunction with surgery to help control the area, but it can also be used as the first line of treatment for patients who cannot be surgically removed.

Description

Squamous cell carcinoma is a skin cancer that can be fatal. Small, flat cells called squamous cells are present in the skin's epidermis. When these cells develop into cancer, they frequently turn into round, flat or raised skin tumors. On occasion, the skin around the tumor will turn red and swell. Additionally, the penis or vulva may develop squamous cell carcinoma. Actinic keratosis, a precancerous skin growth, can occasionally lead to squamous cell carcinoma. People with blue eyes, light skin, light hair, childhood freckles, and those who frequently come into contact with direct sunlight are more likely to develop this skin cancer. Other risk factors include exposure to industrial pollutants like arsenic, tar, and industrial oils, as well as the use of immunosuppressants (drugs that impair immunity). Squamous cell carcinoma typically starts out as tiny, painless, red patches or spots on the skin that slowly enlarge and may ulcerate. The head, ears, and hands are typical locations where it develops on skin that is frequently exposed to direct sunlight. Squamous cell carcinoma is primarily diagnosed through biopsy. This entails taking a small piece of tissue from the suspected area and examining it in a lab. CSCs can manifest as raised growths with a central depression, rough, thickened, or warty skin, open sores, red, scaly plaques, or rough, thickened plaques. CSCs can itch, shed, or bleed occasionally. The body's sun-exposed regions are where lesions most frequently develop. Even though the majority of CSCs can be treated quickly and effectively, if they are allowed to spread, they can be fatal or even disabling. CSCs have the potential to become aggressive, penetrate the skin more deeply, and spread to other body regions if left untreated.

Squamous Cell Skin Cancer (Epidemiology)

The incidence of cSCC is continuing to rise globally despite growing public understanding of the factors that contribute to skin cancer and the value of limiting time spent in the sun. According to a study that examined skin cancer cases in South Korea between 1999 and 2014, the incidence of the disease increased steadily over time, with average annual percentage changes for men and women of 3 and 6 points, respectively. In Rochester, Minnesota, the age-adjusted incidence of SCC increased from 47 in 1984-1986 to 100 in 1990-1992, while the incidence rate in men increased from 126 per 100,000 to 191 cases. A number of factors, including aging populations, increased sensitivity, increased sunscreen use, and environmental factors like ozone depletion, are thought to be contributing to this increased incidence. Additionally, the number of patients undergoing solid organ transplantation and immunosuppressive therapy is rising for many rheumatic and dermatological diseases. The risk of developing SCC is significantly higher for people who have received solid organ transplants, as was already mentioned. Additionally, this group may have a higher incidence of metastases. The most frequent cancer found in Americans is skin cancer. Because these cases are not reported to cancer registries, it is challenging to estimate the number of kSCCs. According to one report, more than 3.3 million Americans received treatment for more than 5.4 million cases of nonmelanoma skin cancer in 2012. In contrast, the American Cancer Society predicts that in 2017, there will be approximately 1.7 million new cancer diagnoses in the country. Basal cell carcinomas (BCC) account for about 80% of non-melanoma skin cancers, while squamous cell carcinomas account for 20%. (SCC) Cancer. cSCC is one of the most prevalent types of skin cancer in the US and the second most common type of skin cancer overall.

Squamous Cell Skin Cancer -Current Market Size & Forecast Trends

The market for squamous cell carcinoma (SCC) of the skin is projected to grow significantly, with estimates indicating a value of approximately USD 2.79 billion in 2024, expected to reach around USD 4.89 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.5% during this period. The increasing incidence of skin cancers, particularly SCC, is driving this growth, along with advancements in treatment options such as immunotherapy and targeted therapies. The rise in awareness about skin cancer and its risk factors, including UV exposure, is also contributing to market expansion.

Electrical curettage (EDand; C) is a treatment option for cutaneous squamous cell carcinoma (cSCC) of low risk that affects the trunk and extremities. The main options for treating aggressive cSCC are surgical resection and Moss microsurgery; these procedures have comparable cure rates when using the right patients. In order to better control the area, radiation therapy is frequently used in conjunction with surgery; however, it is also an option for patients who cannot undergo surgery. Chemotherapy may be thought of as adjuvant therapy in certain high-risk cSCC cases. Epidermal growth factor receptor (EGFR) inhibitors may be used in conjunction with surgery, according to newly available evidence. Systemic chemotherapy may be considered for metastatic cSCC. An essential component of managing cSCC is prevention. Approaches aimed at reducing UV exposure are a cornerstone of cSCC prevention due to the central role that ultraviolet radiation (UVR) plays in the pathogenesis of the disease. Precancerous skin lesions can be successfully treated with a variety of methods, such as actinic keratosis and localized carcinomas. The majority of these procedures can be completed without hospitalization. Chemotherapy administered locally and systemically is used to treat cutaneous squamous cell carcinoma (SCC) without surgery. Patients with actinic keratosis or chronic sun exposure are treated with a variety of topical medications. Head and neck squamous cell carcinoma survivorship can also be increased by combining chemotherapy with radiation therapy, but this approach is not without risks. The first systemic medication authorized for the treatment of advanced cutaneous SCC is the immunotherapy cemiplimab. In the metastatic arm of the EMPOWER-CSCC-1 study, cemiplimab was administered to 28 of 59 patients (47.5%; median follow-up: 7.9%). Over six months was the average response time for 57% of patients.

Report Highlights

Squamous Cell Skin Cancer - Current Market Trends

Squamous Cell Skin Cancer - Current & Forecasted Cases across the G8 Countries

Squamous Cell Skin Cancer - Market Opportunities and Sales Potential for Agents

Squamous Cell Skin Cancer - Patient-based Market Forecast to 2035

Squamous Cell Skin Cancer - Untapped Business Opportunities

Squamous Cell Skin Cancer - Product Positioning Vis-a-vis Competitors' Products

Squamous Cell Skin Cancer - KOLs Insight